• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cellular physiology. >A prognostic eight-lncRNA expression signature in predicting recurrence of ER-positive breast cancer receiving endocrine therapy
【24h】

A prognostic eight-lncRNA expression signature in predicting recurrence of ER-positive breast cancer receiving endocrine therapy

机译：预后eight-lncRNA表达式签名预测雌激素受体阳性乳腺癌的复发癌症接受内分泌治疗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Long noncoding RNAs (IncRNAs) have the main role in the tumorigenesis of breast cancer. In the present study, IncRNA expression profiling was collected to identify a IncRNA expression signature from the Gene Expression Omnibus database. An eight-IncRNA signature was established to predict the survival of patients with estrogen receptor (ER)-positive breast cancer receiving endocrine therapy. Patients were separated into a low-risk group and a high-risk group based on this signature. Patients in high-risk group have worse survival compared to those in low-risk group using Kaplan-Meier curve analysis with log-rank test. Receiver operating characteristic analysis suggested good diagnostic efficiency of the eight-lncRNA signature. When adjusting the clinical features, including age, grade, lymph node status, and tumor size, this signature was independently associated with the relapse-free survival. The prognostic value of the IncRNA prognostic model was then validated in validation sets. When validated in a cohort of patients treated with neoadjuvant chemotherapy and endocrine therapy, this signature demonstrated good performance as well. Besides, we have built a nomogram that integrated the conventional clinicopatho-logical features and the eight-lncRNA-based signature. To sum up, our results indicated that the eight-lncRNA prognostic model was a reliable tool to group patients at high and low risk of disease relapse. This signature may have possible implication in prognostic evaluations of patients with ER-positive breast cancer receiving endocrine therapy.
机译：长非编码rna (IncRNAs)的主要角色在乳腺癌的肿瘤发生。本研究,IncRNA表达分析收集识别IncRNA表达式从基因表达综合签名数据库。建立了预测患者的生存与雌激素受体(ER)阳性乳腺癌癌症接受内分泌治疗。分为一群低风险和高风险组在此基础上签名。高危人群相比更糟糕的生存那些在低风险组使用kaplan meier曲线分析与生存率较。分析显示良好的诊断特征eight-lncRNA签名的效率。调整临床特征,包括年龄、年级,淋巴结状态,肿瘤大小,这签名是独立相关复发存活率。然后IncRNA预后模型验证验证集。患者新辅助化疗和内分泌治疗,这个签名展示了良好的性能。我们已经建立了一个集成的诺模图传统clinicopatho-logical特性和eight-lncRNA-based签名。结果表明,eight-lncRNA预测模型是一个可靠的工具组患者疾病复发风险高和低。这个签名可能可能的含义患者的预后评估雌激素受体阳性乳腺癌内分泌治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号